(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199331 A1

(51) International Patent Classification:
*C12N 5/0775* (2010.01) *C12N 15/87* (2006.01)
*A61K 9/00* (2006.01) *A61K 48/00* (2006.01)
*A61K 35/28* (2015.01)

(21) International Application Number:
PCT/US2025/020721

(22) International Filing Date:
20 March 2025 (20.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,832 22 March 2024 (22.03.2024) US

(71) Applicant: **SANBIO, INC.** [US/US]; c/o Berkins & Takami, 809 Walker Avenue, Ste. 1, Oakland, California 94610 (US).

(72) Inventors: **KLEIN, Barbara**; 923 Shell Blvd., Apt. 102, Foster City, California 94404 (US). **ANDREWS-ZWILLING, Yaisa**; 96 Ellis Road, Havertown, Pennsylvania 19083 (US). **WARRAICH, Zuha**; 255 Berry Street, Unit 106, San Francisco, California 94158 (US). **PAZ, Jeanne T.**; 1650 Owens Street, San Francisco, California 94158 (US).

(74) Agent: **XU, Daniel X.** et al.; Levine Bagade Han LLP, 2479 E. Bayshore Road, Suite 195, Palo Alto, California 94303 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

WO 2025/199331 A1

(54) Title: METHODS AND COMPOSITIONS FOR TREATING CORTICAL HYPEREXCITABILITY AND REVERSING STROKE-INDUCED CHANGES IN GENE EXPRESSION AND PROTEIN EXPRESSION





FIG. 1

(57) Abstract: Disclosed are compositions and methods for treating cortical hyperexcitability and reversing stroke-induced changes in gene expression and protein expression. For example, the methods can comprise administering vandefitemcel to a region of the brain of a subject to reduce chronic cortical hyperexcitability in the subject. Also disclosed are methods and blood biomarker panels for assessing an efficacy of a stem cell treatment for a chronic condition caused by stroke.

*[Continued on next page]*

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*